



Amgen To Build State-Of-The-Art Manufacturing Facility In Singapore

January 16, 2013

THOUSAND OAKS, Calif., Jan. 16, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced plans to build a new manufacturing facility in the Tuas Biomedical Park area of Singapore. Over the next several years, Amgen anticipates investing approximately \$200 million to build an innovative new facility, which will initially focus on expanding Amgen's manufacturing capability for monoclonal antibodies. The facility will be capable of manufacturing both clinical and commercial products.

"Amgen is pleased to be planning for a new world-class facility in Singapore as part of our global expansion strategy. Singapore is an ideal location to further our manufacturing efforts based on its rich talent pool and friendly business environment," said Madhu Balachandran, executive vice president of Operations at Amgen.

Construction is expected to begin in the next few months, and the site will be staffed with both new recruits and experienced staff. Amgen is currently partnering with local universities to recruit for a number of positions in Manufacturing and Quality.

About Amgen

As one of the industry's original innovators, Amgen has extensive knowledge and first-hand expertise in clinical and commercial manufacturing of biotechnology-based medicines as well as a track record of safely and reliably delivering medicines to patients who need them.

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com. Follow us on www.twitter.com/amgen.

Forward-Looking Statements

This news release contains forward-looking statements that involve significant risks and uncertainties, including those discussed below and others that can be found in our Form 10-K for the year ended Dec. 31, 2011, and in our periodic reports on Form 10-Q and Form 8-K. Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. The Company's results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments (domestic or foreign) involving current and future products, sales growth of recently launched products, competition from other products (domestic or foreign) and difficulties or delays in manufacturing our products. In addition, sales of our products are affected by reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and health care cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We, or others, could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock.

CONTACT: Amgen, Thousand Oaks
Ashleigh Koss, 805-313-6151 (media)
Arvind Sood, 805-447-1060 (investors)

(Logo: <http://photos.prnewswire.com/prnh/20081015/AMGENLOGO>)

SOURCE Amgen